Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Springfield Clinic

Neither a doctor nor a teaching hospital

Research payments

$1,113,015

275 payments

Through program year 2025, Springfield Clinic is reported as receiving $1,113,015 in research payments, across 275 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $392,275 210
2024 Research $242,857 5
2023 Research $7,599 3
2022 Research $28,543 20
2021 Research $58,974 3
2020 Research $9,821 3
2019 Research $372,945 31

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $576,231 206 payments
  2. Novartis Pharmaceuticals Corporation $249,273 4 payments
  3. Amgen Inc. $137,084 8 payments
  4. Merck Sharp & Dohme Corporation $54,658 22 payments
  5. Genzyme Corporation $28,000 1 payment
  6. AbbVie, Inc. $22,203 15 payments
  7. Samsung Medison Co., Ltd. $15,000 2 payments
  8. Insmed, Inc. $14,213 11 payments
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $11,685 3 payments
  10. E.R. Squibb & Sons, L.L.C. $4,670 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) $347,656 164 payments
  2. A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 We $242,986 2 payments
  3. BI 456906 in NAFLD $210,925 2 payments
  4. Enbrel RA Remission Study $77,960 5 payments
  5. ABP 654 P3 PsO Study $58,484 2 payments
  6. Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis $28,000 1 payment
  7. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU $27,563 5 payments
  8. A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA $26,604 16 payments
  9. EASi-HF Reduced ? A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $17,649 40 payments
  10. EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $11,685 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record